

Syntara Quarterly Shareholder Report and Investor Briefing

Tuesday 30 April 2024 at 11.00am AEST

Syntara Limited (ASX: SNT) will release its Quarterly Shareholder Report on the morning of 30 April 2024.

Shareholders, investors and interested parties are invited to participate in a virtual investor briefing by the Company's Chief Executive Officer Mr Gary Phillips at 11.00am AEST on Tuesday 30 April 2024.

The event will consist of a short presentation of the Company's progress over the past quarter and future plans, followed by a Q&A session.

The event is free to attend, and investors should register in advance using the following registration link: https://us02web.zoom.us/webinar/register/WN_tMtQRCXFRt2P3q-LTDByoA.

Upon registration, instructions for joining the session will be sent via email.

A recording will be available at the above link shortly after the conclusion of the presentation, and the replay will also be available via the Company's website and social media channels.

Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au

#ENDS#

SOURCE:

Syntara Limited (ASX: SNT),
Sydney, Australia
(ABN: 75 082 811 630)

AUTHORISED FOR RELEASE TO ASX BY:

Syntara Limited Company Secretary.
Contact: David McGarvey, Chief Financial
Officer, and Company Secretary:

+61 2 9454 7200,
david.mcgarvey@syntaraTX.com.au

CONTACT:**Syntara investor / media relations:**

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

JOIN THE SYNTARA MAILING LIST [HERE](#)





About Syntara

Syntara Limited (ABN: 75 082 811 630) is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.

Syntara is managing three phase 2 clinical studies in diseases of high unmet need with a further two potential phase 1c/2 studies being evaluated for 2024. Lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. SNT-5505 has already achieved FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for development in myelofibrosis. After encouraging phase 2a trial results when used as a monotherapy in myelofibrosis, SNT-5505 is now being studied with a JAK inhibitor in a further phase 2 myelofibrosis study with interim data by Q4 2024. The protocol for another phase 1c/2 study with SNT-5505 in patients with a blood cancer called myelodysplastic syndrome is in development and expected to commence recruitment in 2H 2024.

Syntara is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs as part of an ongoing collaboration with Professor Fiona Wood and the University of Western Australia. SNT-4728 is being studied in collaboration with Parkinson's UK as a best-in-class SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson's by reducing neuroinflammation.

Other Syntara drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.

Syntara developed two respiratory products available in world markets (Bronchitol® for cystic fibrosis and Aridol®- a lung function test), for which it receives royalties.

Syntara is listed on the Australian Securities Exchange, code SNT. The company's management and scientific discovery team are based in Sydney, Australia. www.syntaraTX.com.au.

Forward-Looking Statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.